LCS
ARLZ

Levin Capital Strategies’s Aralez Pharmaceuticals Inc. ARLZ Stock Holding History

Levin Capital Strategies’s Portfolio ARLZ Stock Details ARLZ Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q3 		– Sell
-66,991
Closed -$221K – 394
2016
Q2 		$221K Buy
+66,991
New +$253K ﹤0.01% 298

Other funds holding ARLZ

PCM
PAR Capital Management Boston, Massachusetts $3.45B AUM 28.5% 1-Year Est. Return
BC
Broadfin Capital New York $747M AUM 100.56% 1-Year Est. Return
JAM
JW Asset Management Miami Beach, Florida $244M AUM 71.51% 1-Year Est. Return
ECP
Elk Creek Partners Denver, Colorado $582M AUM 10.23% 1-Year Est. Return
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
TLCM
Tiger Legatus Capital Management New York $62.4M AUM 24.33% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
CAD
Craig A. Drill $24.4M AUM 13.42% 1-Year Est. Return
HVC
Healthcare Value Capital Woodcliff Lake, New Jersey $50.7M AUM 24.72% 1-Year Est. Return
VOAM
Vertex One Asset Management Vancouver, British Columbia, Canada $434M AUM 37.82% 1-Year Est. Return

Levin Capital Strategies's ARLZ Position: Q3 2016 in Review

Levin Capital Strategies sold out of Aralez Pharmaceuticals Inc. (ARLZ) in Q3 2016, closing a stake of 66,991 shares — an estimated $221K sold.

Levin Capital Strategies first reported a position in ARLZ in Q2 2016 and held it in 1 quarter. The position peaked at $221K in Q2 2016. 83 funds tracked by Wall St. Rank hold ARLZ as of Q3 2016.

  • Levin Capital Strategies reported no remaining Aralez Pharmaceuticals Inc. position as of Q3 2016 after selling out during the quarter.
  • Levin Capital Strategies sold 66,991 Aralez Pharmaceuticals Inc. shares in Q3 2016, an estimated $221K.
  • Levin Capital Strategies first reported a position in Aralez Pharmaceuticals Inc. in Q2 2016 and held it in 1 quarter.
  • Levin Capital Strategies's Aralez Pharmaceuticals Inc. position peaked at $221K in Q2 2016.
  • 83 funds tracked by Wall St. Rank held Aralez Pharmaceuticals Inc. as of Q3 2016.

Based on Levin Capital Strategies's 13F filing for Q3 2016, filed 14 Nov 2016.